XOMA Royalty (NASDAQ:XOMA) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of XOMA Royalty (NASDAQ:XOMA) from a hold rating to a strong sell rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

Other analysts have also issued reports about the stock. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. HC Wainwright dropped their price target on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Wall Street Zen downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a research report on Friday, December 12th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $61.60.

XOMA Royalty Stock Down 0.4%

NASDAQ:XOMA opened at $26.86 on Tuesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The stock has a 50-day simple moving average of $26.15 and a 200 day simple moving average of $30.70. XOMA Royalty has a one year low of $18.35 and a one year high of $39.92. The company has a market capitalization of $332.53 million, a price-to-earnings ratio of 36.30 and a beta of 0.86.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XOMA. Woodline Partners LP raised its position in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after buying an additional 12,284 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in XOMA Royalty during the second quarter valued at about $370,000. Geode Capital Management LLC raised its holdings in XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after acquiring an additional 16,929 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 2,019 shares during the period. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.